Amedisys price target raised to $82 from $69 at Craig-Hallum. Craig-Hallum analyst Kevin Ellich raised his price target for Amedisys to $82 from $69 after the company’s Q1 results beat estimates driven by solid same-store home health and hospice volume growth, better than expected home health revenue per episode growth, and EBITDA margin expansion in each of its business segments. The analyst reiterates a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.